Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6

Journal of General Virology

Volumn 86, Issue 4, 2005, Pages 1001-1007

  Lagrange, Magali ^a   Charbonnier, Sebastian ^a   Orfanoudakis, Georges ^a   Robinson, Philip ^a   Zanier, Katia ^a   Masson, Murielle ^a   Lutz, Yves ^b,c   Trave, Gilles ^a   Weiss, Etienne ^a   Deryckere, François ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c CENTRE DE NEUROCHIMIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEASOME; PROTEIN E6; PROTEIN P53; UBIQUITIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN COS1; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; VIRUS TRANSCRIPTION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CERCOPITHECUS AETHIOPS; COS CELLS; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; REPRESSOR PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 20144388587     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.80607-0     Document Type: Article

References (29)

1. Banks, L., Matlashewski, G. & Crawford, L. (1986). Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159, 529-534.
2. Bedell, M. A., Jones, K. H. & Laimins, L. A. (1987). The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and rat-1 cells. J Virol 61, 3635-3640.
3. Choulier, L., Orfanoudakis, G., Robinson, P., Laune, D., Ben Khalifa, M., Granier, C., Weiss, E. & Altschuh, D. (2002). Comparative properties of two peptide-antibody interactions as deduced from epitope delineation. J Immunol Methods 259, 77-86.
4. Clifford, G. M., Smith, J. S., Plummer, M., Munoz, N. & Franceschi, S. (2003). Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88, 63-73.
5. Cooper, B., Schneider, S., Bohl, J., Jiang, Y., Beaudet A. & Vande Pol, S. (2003). Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. Virology 306, 87-99.
6. Crook, T., Tidy, J. A. & Vousden, K. H. (1991). Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67, 547-556.
7. Deryckere, F. & Burgert, H. G. (1996). Early region 3 of adenovirus type 19 (subgroup D) encodes an HLA-binding protein distinct from that of subgroups B and C. J Virol 70, 2832-2841.
8. Foster, S. A., Demers, G. W., Etscheid, B. G. & Galloway, D. A. (1994). The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 68, 5698-5705.
9. Gewin, L. & Galloway, D. A. (2001). E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J Virol 75, 7198-7201.
10. Giovane, C., Trav, G., Briones, A., Lutz, Y., Wasylyk, B. & Weiss, E. (1999). Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53. J Mol Recognit 12, 141-152.
11. Green, S., Isseman, I. & Sheer, E. (1988). A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res 16, 369.
12. Grm, H. S. & Banks, L. (2004). Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. J Gen Virol 85, 2815-2819.
13. Herber, R., Liem, A., Pitot, H. & Lambert, P. F. (1996). Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 70, 1873-1881.
14. Huibregtse, J. M., Scheffner, M. & Howley, P. M. (1993). Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 13, 4918-4927.
15. Li, X. & Coffino, P. (1996). High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 70, 4509-4516.
16. Liu, Y., Chen, J. J., Gao, Q., Dalal, S., Hong, Y., Mansur, C. P., Band, V. & Androphy, E. J. (1999). Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 73, 7297-7307.
17. Mantovani, F. & Banks, L. (2001). The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20, 7874-7887.
18. Masson, M., Hindelang, C., Sibler, A. P., Schwalbach, G., Trave, G. & Weiss, E. (2003). Preferential nuclear localization of the human papillomavirus type 16 E6 oncoprotein in cervical carcinoma cells. J Gen Virol 84, 2099-2104.
19. Matlashewski, G., Schneider, J., Banks, L., Jones, N., Murray, A. & Crawford, L. (1987). Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J 6, 1741-1746.
20. Pim, D. & Banks, L. (1999). HPV-18 E6I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 18, 7403-7408.
21. Pim, D., Thomas, M., Javier, R., Gardiol, D. & Banks, L. (2000). HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene 19, 719-725.
22. Ristriani, T., Nomine, Y., Masson, M., Weiss, E. & Trave, G. (2001). Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6. J Mol Biol 305, 729-739.
23. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
24. Schwalbach, G., Sibler, A. P., Choulier, L., Deryckere, F. & Weiss, E. (2000). Production of fluorescent single-chain antibody fragments in Escherichia coli. Protein Expr Purif 18, 121-132.
25. Sibler, A. P., Nordhammer, A., Masson, M., Martineau, P., Trave, G. & Weiss, E. (2003). Nucleocytoplasmic shuttling of antigen in mammalian cells conferred by a soluble versus insoluble single-chain antibody fragment equipped with import/export signals. Exp Cell Res 286, 276-287.
26. Song, S., Pitot, H. C. & Lambert, P. F. (1999). The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol 73, 5887-5893.
27. Vousden, K. H., Doniger, J., DiPaolo, J. A. & Lowy, D. R. (1988). The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res 3, 167-175.
28. Walboomers, J. M., Jacobs, M. V., Manos, M. M. & 7 other authors (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12-19.
29. Watanabe, S., Kanda, T. & Yoshiike, K. (1989). Human papillomavirus type 16 transformation of primary human embryonic fibroblasts requires expression of open reading frames E6 and E7. J Virol 63, 965-969.